Point of Care (POC) Lipid Diagnostics Market, By Application (Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease), By Instrument (Roche Cobas b 101, Abaxis Piccolo Xpress, Roche Reflotron, Alere Cholestech LDX, and others) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) Analysis, Share, Trends, Size, & Forecast From 2016 2027- COVID- 19 Updated
- Published Date: 2020-10-13
- Report ID: 1768
- Pages: 206
-
Format:
REPORT HIGHLIGHT
The Point of Care Lipid Diagnostics market is estimated to represent a global market of USD 210.5 million by 2019 with growth rate of 3.3%.
Market Dynamics
Point of care lipid testing is the testing of lipid content in order to improve the risk of cardiovascular disorders. Growing geriatric population coupled with rising sedentary lifestyle and unhealthy food habits are anticipated to stimulate the market growth. According to the World Health Organization (WHO), global population between the age group, 65 years and above is projected to rise from 7% in 2000 to 16% in 2050. Aging heightens the risk of chronic diseases such as cardiovascular diseases and diabetes. Lipid testing is an important parameter for monitoring variety of chronic diseases including diabetes, asthma, arthritis and other cardiovascular diseases. Increasing prevalence of such diseases is also expected to drive the market growth significantly. As per the statistics released by the WHO, patients affected with diabetes has risen from 108 million (1980) to 422 million (2014). Similarly, the International Diabetes Federation stated that around 425 million patients have diabetes globally. Growing disease incidences is projected to boost the demand for accurate, speedy and user-friendly diagnostic method, hence, driving the market growth.
Application Takeaway
The global Point of Care Lipid testing market is segmented into three levels: applications, instruments, and geography. Application segment is categorized as hyperlipidemia, hypertriglyceridemia, familial hypercholesterolemia, hyperlipoproteinemia, Tangier disease, and others. Hyperlipidemia segment has captured the large share of the total market. As per the Centres for Disease Control and Prevention, more than 78 million people suffer from abnormal cholesterol level in 2012 which is expected to increase in future years. Such facts will boost the use of point of care lipid diagnosis, leading to augment the market growth to great extent. On another hand, hypertriglyceridemia is projected to gain significant market share over the forecast period owing to the development of novel products. The instrument segment is divided into Roche Cobas b 101, Abaxis Piccolo Xpress, Roche Reflotron, Alere Cholestech LDX, Alere Afinion, Samsung LABGEO PT10, and Cardiocheck.
COVID-19 Impact and Recovery Analysis
The novel COVID-19 has put the world on a standstill, affecting major operations, leading to an industrial catastrophe. However, this market is positively affected due to this outbreak. This report presented by AnalystView Market Insights contains a thorough analysis of the pre and post COVID-19 market scenarios. The report includes all the recent development and changes recorded during the COVID-19 outbreak and comprehends the analysis of top performer segments and marginal growth segment in blood culture test sector.
Key Vendor Takeaway
Samsung, Roche Diagnostics, Alere, Abaxis, Inc., and Bio-Rad Laboratories are profiled in the study. Extensive product portfolio and strategic collaborations with small-scale industry participants are considered to be the key strategies of these players. Other market leaders are also aggressively involved in new product development and expansion of distribution channels to capture a larger share of the market. Moreover, the companies are highly inclined toward maintaining competition in the market as well as delivering economic value to customers and satiate unmet demands.
The market size and forecast for each segment has been provided for the period 2016 to 2027, considering 2019 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2021 to 2027 for every reported segment.
The years considered for the study are:
Historical Year 2016 to 2018
Base Year 2019
Estimated Year 2020
Projected Year 2027
The proposed reports analyse and evaluates the COVID-19 impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.
TABLE OF CONTENT
1. POC LIPID DIAGNOSTICS MARKET OVERVIEW
1.1. Study Scope
1.2. Base Year
1.3. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Key Market Facts
2.2. Geographical Scenario
2.3. Companies in the Market
3. POC LIPID DIAGNOSTICS KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. POC LIPID DIAGNOSTICS INDUSTRY STUDY
4.1. Porters Analysis
4.2. Regulatory Framework Analysis
4.3. Market Attractiveness Analysis
4.4. Value Chain Analysis
5. POC LIPID DIAGNOSTICS MARKET LANDSCAPE
5.1. Market Share Analysis
6. POC LIPID DIAGNOSTICS MARKET BY APPLICATION:
6.1. Overview
6.2. Hyperlipidemia
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
6.3. Hypertriglyceridemia
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
6.4. Familial hypercholesterolemia
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
6.5. Hyperlipoproteinemia
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
6.6. Tangier disease
6.6.1. Overview
6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
6.7. Others
6.7.1. Overview
6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
7. POC LIPID DIAGNOSTICS MARKET BY INSTRUMENT:
7.1. Overview
7.2. Roche Cobas b 101
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
7.3. Abaxis Piccolo Xpress
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
7.4. Roche Reflotron
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
7.5. Alere Cholestech LDX
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
7.6. Alere Afinion
7.6.1. Overview
7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
7.7. Samsung LABGEO PT10
7.7.1. Overview
7.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
7.8. Cardiocheck
7.8.1. Overview
7.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8. POC LIPID DIAGNOSTICS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.2.3. U.S.
8.2.3.1. Overview
8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.2.4. Canada
8.2.4.1. Overview
8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.3. Europe
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.3.3. France
8.3.3.1. Overview
8.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.3.4. Germany
8.3.4.1. Overview
8.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.3.5. Rest of Europe
8.3.5.1. Overview
8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.4. Asia Pacific (APAC)
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.4.3. China
8.4.3.1. Overview
8.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.4.4. India
8.4.4.1. Overview
8.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.4.5. Rest of APAC
8.4.5.1. Overview
8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.5. Rest of the World
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.5.3. Latin America
8.5.3.1. Overview
8.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
8.5.4. Middle East and Africa
8.5.4.1. Overview
8.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 2027, (US$ Million)
9. KEY VENDOR ANALYSIS
9.1. Samsung
9.1.1. Company Overview
9.1.2. SWOT Analysis
9.1.3. Key Developments
9.2. Roche Diagnostics
9.2.1. Company Overview
9.2.2. SWOT Analysis
9.2.3. Key Developments
9.3. Alere
9.3.1. Company Overview
9.3.2. SWOT Analysis
9.3.3. Key Developments
9.4. Abaxis, Inc.
9.4.1. Company Overview
9.4.2. SWOT Analysis
9.4.3. Key Developments
9.5. Bio-Rad Laboratories
9.5.1. Company Overview
9.5.2. SWOT Analysis
9.5.3. Key Developments
*Client can request additional company profiling as per specific requirements
10. 360 DEGREE ANALYSTVIEW
11. APPENDIX
11.1. Research Methodology
11.2. Abbreviations
11.3. Disclaimer
11.4. Contact Us
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
